Revolve Wealth Partners LLC Has $367,000 Position in Merck & Co., Inc. $MRK

Revolve Wealth Partners LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 4,642 shares of the company’s stock after acquiring an additional 178 shares during the period. Revolve Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $367,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Cornerstone Wealth Group LLC raised its stake in Merck & Co., Inc. by 1.9% during the 2nd quarter. Cornerstone Wealth Group LLC now owns 21,558 shares of the company’s stock valued at $1,707,000 after purchasing an additional 409 shares during the period. Kellett Wealth Advisors LLC increased its stake in shares of Merck & Co., Inc. by 15.3% in the second quarter. Kellett Wealth Advisors LLC now owns 2,871 shares of the company’s stock worth $227,000 after acquiring an additional 381 shares during the last quarter. Community Bank N.A. increased its stake in shares of Merck & Co., Inc. by 2.0% in the second quarter. Community Bank N.A. now owns 115,327 shares of the company’s stock worth $9,128,000 after acquiring an additional 2,306 shares during the last quarter. NorthRock Partners LLC increased its stake in shares of Merck & Co., Inc. by 20.2% in the second quarter. NorthRock Partners LLC now owns 39,328 shares of the company’s stock worth $3,140,000 after acquiring an additional 6,614 shares during the last quarter. Finally, Concord Wealth Partners increased its stake in shares of Merck & Co., Inc. by 34.5% in the second quarter. Concord Wealth Partners now owns 2,056 shares of the company’s stock worth $163,000 after acquiring an additional 527 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Down 0.4%

Merck & Co., Inc. stock opened at $85.64 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market capitalization of $213.90 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.88 and a beta of 0.37. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $111.58. The company’s fifty day moving average price is $83.58 and its two-hundred day moving average price is $81.40.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th were given a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Monday. They issued a “neutral” rating and a $95.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $105.00.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.